Why the study?
Does pimobendan improve hemodynamics, symptoms, and quality of life in patients with heart failure?
Population
Japanese patients with acute and chronic heart failure (n=241 for safety analysis)
Comparison
Pimobendan vs Placebo
Design
Review, double-blind (for the included trials)
Follow-up
8 weeks to long-term
Authors
Loading...
Supports symptomatic benefit in HF; leaves open need for RCTs before any practice consideration.
Does pimobendan improve hemodynamics, symptoms, and quality of life in patients with heart failure?
Pimobendan demonstrates efficacy in improving hemodynamics, symptoms, and physical activity in Japanese patients with heart failure, with an acceptable safety profile.
Kazuzo Kato (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: